PTC Therapeutics, Oragenics, GT Biopharma among healthcare movers
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 20 2024
0mins
Should l Buy PTCT?
Source: SeekingAlpha
- Gainers: GT Biopharma (GTBP) +180%, Oragenics (OGEN) +39%, Dyne Therapeutics DYN +22%, NKGen Biotech (NKGN) +24%, PTC Therapeutics (PTCT) +21%
- Losers: Lucy Scientific Discovery (LSDI) -18%, biote (BTMD) -10%, Aspira Women's Health (AWH) -10%, Compugen CGEN -10%, Flora Growth (FLGC) -7%
- S&P 500 Health Care Sector: Decreased by 0.1% to 1701.36
- Health Care Equipment & Services: Declined by 0.33% to 1964.79
- Pharmaceuticals, Biotechnology & Life Science Index: Increased by 0.06% to 1398.51
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PTCT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PTCT
Wall Street analysts forecast PTCT stock price to rise
14 Analyst Rating
8 Buy
5 Hold
1 Sell
Moderate Buy
Current: 68.750
Low
54.00
Averages
78.18
High
118.00
Current: 68.750
Low
54.00
Averages
78.18
High
118.00
About PTCT
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PTC Appoints Biotechnology Investment Banker to Board
- New Board Member: PTC Therapeutics announced the appointment of Jessica Chutter to its Board of Directors, who brings over 40 years of extensive experience in biotechnology investment banking from Morgan Stanley, having been involved in approximately $80 billion in capital raising and $85 billion in strategic transactions, which is expected to significantly support the company's future growth.
- Industry Pioneer: Ms. Chutter is widely regarded as a pioneer in the field of biotechnology investment banking, and her addition is anticipated to provide PTC with deep industry insights and strategic guidance, helping the company further solidify its position in the competitive biopharmaceutical market.
- Management Confidence: PTC CEO Matthew B. Klein stated that Chutter was a trusted advisor to PTC, and her broad vision and successful company-building experience will make her a valued board member, driving the company forward.
- Future Outlook: Ms. Chutter expressed admiration for PTC's transformation in recent years, noting that the company has become a strong and execution-oriented biotech firm well-positioned for future success, indicating a positive outlook for the company in the industry.
See More
PTC Appoints Biotechnology Expert to Board
- New Board Member: PTC Therapeutics announced the appointment of Jessica Chutter to its Board of Directors, who brings over 40 years of extensive experience in biotechnology investment banking from Morgan Stanley, having been involved in approximately $80 billion in capital raising and $85 billion in strategic transactions, which is expected to significantly support the company's future growth.
- Industry Pioneer: Ms. Chutter is widely regarded as a pioneer in the field of biotechnology investment banking, and her addition to the board will provide PTC with deep industry knowledge and strategic insights, helping the company further solidify its position in the competitive biopharmaceutical market.
- Management Confidence: PTC's Chairman, Michael Schmertzler, stated that Chutter's addition will enhance collaboration between the board and management team, driving the company's strategic development, reflecting confidence in the company's transformation.
- Future Outlook: Ms. Chutter expressed admiration for PTC's transformation over recent years and looks forward to collaborating with management to further drive innovation and market expansion in the rare disease sector, enhancing treatment options for patients.
See More
RTW Investments Takes New Stake in Apellis Pharmaceuticals
- New Investment Move: RTW Investments initiated a new position in Apellis Pharmaceuticals during Q4 2026, acquiring 7,666,764 shares valued at $192.59 million, indicating confidence in the biotech firm’s future prospects.
- Market Performance Analysis: Currently priced at $17.21, Apellis shares have declined 29% over the past year, significantly underperforming the S&P 500, which has risen 15% in the same period, reflecting market caution regarding its growth trajectory.
- Revenue and Growth Potential: Apellis generated approximately $689 million in product revenue last year, with its flagship therapy alone contributing about $587 million, demonstrating real demand and potential for market share expansion in the rare disease sector.
- Portfolio Strategy: Apellis accounts for 1.93% of RTW's reportable AUM, suggesting a strategic pivot towards more stable revenue streams while still maintaining exposure to high-growth opportunities within its broader investment portfolio.
See More
RTW Investments Increases Stake in Cogent Biosciences by $116 Million
- Stake Increase: RTW Investments disclosed an acquisition of 4,124,755 shares of Cogent Biosciences in its February 17, 2026 SEC filing, with an estimated transaction value of $115.95 million, indicating strong confidence in the company's future prospects.
- Market Performance: Cogent Biosciences' stock has surged 360% over the past year, compared to a mere 15% gain for the S&P 500, highlighting significant market anticipation for its potential drug launches and positive investor sentiment.
- Financial Position: Currently, Cogent has a market capitalization of $5.4 billion, and despite a net income of -$328.94 million, it boasts approximately $900 million in cash reserves, providing ample runway for R&D and clinical trials through 2028.
- Strategic Implications: The increase in RTW's stake to 2.7% reflects confidence in high-risk biotech investments, particularly with upcoming FDA reviews, where successful clinical outcomes could further propel the stock price upward.
See More
PTC Therapeutics Approves Employee Stock Options
- Stock Option Grants: On March 10, 2026, PTC Therapeutics approved the issuance of a total of 14,550 stock options and 17,515 restricted stock units (RSUs) to 18 new employees, each RSU representing the right to receive one share of common stock upon vesting, aimed at attracting top talent and enhancing employee loyalty.
- Incentive Details: All stock options have an exercise price of $68.56 per share, aligning with the closing price on the grant date, with a 10-year term and a four-year vesting schedule, where 25% vests on the first anniversary and 6.25% every three months thereafter, ensuring continued employee service.
- RSU Vesting Structure: Each RSU will vest over four years, with 25% vesting annually, designed to boost employee engagement and retention through a long-term incentive mechanism that aligns with company goals.
- Strategic Context: PTC Therapeutics focuses on developing innovative medicines for patients with rare diseases, and this incentive program not only aids in attracting new talent but also supports the company's long-term growth strategy in the biopharmaceutical sector by optimizing its global commercial infrastructure.
See More
PTC Therapeutics Approves Employee Stock Options
- Stock Option Grants: On March 10, 2026, PTC Therapeutics approved the issuance of a total of 14,550 stock options and 17,515 restricted stock units (RSUs) to 18 new employees, enhancing employee attraction and boosting the company's competitive edge.
- Incentive Structure: All stock options have an exercise price of $68.56 per share, aligning with the closing price on the grant date, and vest over four years with 25% vesting in the first year and 6.25% every three months thereafter, ensuring long-term employee retention.
- RSU Vesting Arrangement: The RSUs also vest over four years with 25% vesting annually, designed to motivate employees to grow with the company, thereby increasing loyalty and engagement.
- Strategic Company Positioning: PTC Therapeutics focuses on developing innovative medicines for rare diseases, leveraging its scientific expertise and global commercial infrastructure to provide optimal treatment solutions for patients, further solidifying its leadership in the biopharmaceutical industry.
See More
PTC Appoints Biotechnology Investment Banker to Board
- New Board Member: PTC Therapeutics announced the appointment of Jessica Chutter to its Board of Directors, who brings over 40 years of extensive experience in biotechnology investment banking from Morgan Stanley, having been involved in approximately $80 billion in capital raising and $85 billion in strategic transactions, which is expected to significantly support the company's future growth.
- Industry Pioneer: Ms. Chutter is widely regarded as a pioneer in the field of biotechnology investment banking, and her addition is anticipated to provide PTC with deep industry insights and strategic guidance, helping the company further solidify its position in the competitive biopharmaceutical market.
- Management Confidence: PTC CEO Matthew B. Klein stated that Chutter was a trusted advisor to PTC, and her broad vision and successful company-building experience will make her a valued board member, driving the company forward.
- Future Outlook: Ms. Chutter expressed admiration for PTC's transformation in recent years, noting that the company has become a strong and execution-oriented biotech firm well-positioned for future success, indicating a positive outlook for the company in the industry.
See More
PTC Appoints Biotechnology Expert to Board
- New Board Member: PTC Therapeutics announced the appointment of Jessica Chutter to its Board of Directors, who brings over 40 years of extensive experience in biotechnology investment banking from Morgan Stanley, having been involved in approximately $80 billion in capital raising and $85 billion in strategic transactions, which is expected to significantly support the company's future growth.
- Industry Pioneer: Ms. Chutter is widely regarded as a pioneer in the field of biotechnology investment banking, and her addition to the board will provide PTC with deep industry knowledge and strategic insights, helping the company further solidify its position in the competitive biopharmaceutical market.
- Management Confidence: PTC's Chairman, Michael Schmertzler, stated that Chutter's addition will enhance collaboration between the board and management team, driving the company's strategic development, reflecting confidence in the company's transformation.
- Future Outlook: Ms. Chutter expressed admiration for PTC's transformation over recent years and looks forward to collaborating with management to further drive innovation and market expansion in the rare disease sector, enhancing treatment options for patients.
See More
RTW Investments Takes New Stake in Apellis Pharmaceuticals
- New Investment Move: RTW Investments initiated a new position in Apellis Pharmaceuticals during Q4 2026, acquiring 7,666,764 shares valued at $192.59 million, indicating confidence in the biotech firm’s future prospects.
- Market Performance Analysis: Currently priced at $17.21, Apellis shares have declined 29% over the past year, significantly underperforming the S&P 500, which has risen 15% in the same period, reflecting market caution regarding its growth trajectory.
- Revenue and Growth Potential: Apellis generated approximately $689 million in product revenue last year, with its flagship therapy alone contributing about $587 million, demonstrating real demand and potential for market share expansion in the rare disease sector.
- Portfolio Strategy: Apellis accounts for 1.93% of RTW's reportable AUM, suggesting a strategic pivot towards more stable revenue streams while still maintaining exposure to high-growth opportunities within its broader investment portfolio.
See More
RTW Investments Increases Stake in Cogent Biosciences by $116 Million
- Stake Increase: RTW Investments disclosed an acquisition of 4,124,755 shares of Cogent Biosciences in its February 17, 2026 SEC filing, with an estimated transaction value of $115.95 million, indicating strong confidence in the company's future prospects.
- Market Performance: Cogent Biosciences' stock has surged 360% over the past year, compared to a mere 15% gain for the S&P 500, highlighting significant market anticipation for its potential drug launches and positive investor sentiment.
- Financial Position: Currently, Cogent has a market capitalization of $5.4 billion, and despite a net income of -$328.94 million, it boasts approximately $900 million in cash reserves, providing ample runway for R&D and clinical trials through 2028.
- Strategic Implications: The increase in RTW's stake to 2.7% reflects confidence in high-risk biotech investments, particularly with upcoming FDA reviews, where successful clinical outcomes could further propel the stock price upward.
See More
PTC Therapeutics Approves Employee Stock Options
- Stock Option Grants: On March 10, 2026, PTC Therapeutics approved the issuance of a total of 14,550 stock options and 17,515 restricted stock units (RSUs) to 18 new employees, each RSU representing the right to receive one share of common stock upon vesting, aimed at attracting top talent and enhancing employee loyalty.
- Incentive Details: All stock options have an exercise price of $68.56 per share, aligning with the closing price on the grant date, with a 10-year term and a four-year vesting schedule, where 25% vests on the first anniversary and 6.25% every three months thereafter, ensuring continued employee service.
- RSU Vesting Structure: Each RSU will vest over four years, with 25% vesting annually, designed to boost employee engagement and retention through a long-term incentive mechanism that aligns with company goals.
- Strategic Context: PTC Therapeutics focuses on developing innovative medicines for patients with rare diseases, and this incentive program not only aids in attracting new talent but also supports the company's long-term growth strategy in the biopharmaceutical sector by optimizing its global commercial infrastructure.
See More
PTC Therapeutics Approves Employee Stock Options
- Stock Option Grants: On March 10, 2026, PTC Therapeutics approved the issuance of a total of 14,550 stock options and 17,515 restricted stock units (RSUs) to 18 new employees, enhancing employee attraction and boosting the company's competitive edge.
- Incentive Structure: All stock options have an exercise price of $68.56 per share, aligning with the closing price on the grant date, and vest over four years with 25% vesting in the first year and 6.25% every three months thereafter, ensuring long-term employee retention.
- RSU Vesting Arrangement: The RSUs also vest over four years with 25% vesting annually, designed to motivate employees to grow with the company, thereby increasing loyalty and engagement.
- Strategic Company Positioning: PTC Therapeutics focuses on developing innovative medicines for rare diseases, leveraging its scientific expertise and global commercial infrastructure to provide optimal treatment solutions for patients, further solidifying its leadership in the biopharmaceutical industry.
See More
